Document Detail

Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
MedLine Citation:
PMID:  9439979     Owner:  NLM     Status:  MEDLINE    
The mechanism of action of interferon-alpha (IFN-A) in chronic myelogenous leukemia (CML) is not known, but some evidence points at the immune modulation properties of IFN-A. We conducted a prospective analysis on 49 patients with CML in chronic phase treated with IFN-A in order to identify the effect of therapy on different lymphocyte subpopulations as determined by flow cytometric quantification and whether this effect is associated with the response to IFN-A. The absolute number of lymphocytes was similar in all patients regardless of response to IFN-A. In patients achieving a complete cytogenetic response (CCGR) there was a rebound of the absolute count of CD3+, CD4+, CD8+, and CD19+ lymphocytes after discontinuation of therapy with IFN-A. Patients with resistant disease, as well as patients with hematologic response but no cytogenetic response, showed a lower absolute number of CD19+ cells than patients with any cytogenetic response. Patients who achieved a CCGR had a higher absolute number of CD56+ cells than patients with lesser response or no response to IFN-A, and this persisted after discontinuation of therapy. We conclude that an increase in absolute number of CD19+ and CD56+ lymphocytes is observed in CML patients achieving a CCGR with IFN-A compared to patients with lesser responses. These changes could have functional consequences in the control of the disease.
S Sacchi; J Cortes; H Kantarjian; M Talpaz
Related Documents :
3817609 - Alterations in the number of glucocorticoid receptors of circulating lymphocytes in sep...
1364169 - Does c-reactive protein modulate t-lymphocyte function in methotrexate-treated rheumato...
11309029 - Bexarotene capsules and gel for previously treated patients with cutaneous t-cell lymph...
2269379 - Decreased natural killer cell function in patients with classical kaposi's sarcoma.
1270159 - Lymphocyte stimulation and plasma inhibition in patients with malignant neoplasms. a co...
125119 - Transfer factor therapy: evidence for nonspecificity.
8957489 - Surgical treatment of graves' disease: subtotal or total thyroidectomy?
6869659 - Reconstruction of the anterior cruciate ligament using free tendon graft.
19538219 - Plasma levels of 15d-pgj are not altered in multiple sclerosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematopathology and molecular hematology     Volume:  11     ISSN:  1082-8893     ISO Abbreviation:  Hematopathol Mol Hematol     Publication Date:    1997-1998
Date Detail:
Created Date:  1998-02-17     Completed Date:  1998-02-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9608785     Medline TA:  Hematopathol Mol Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  41-7     Citation Subset:  IM    
Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*,  therapeutic use
Interferon Type I, Recombinant / pharmacology*,  therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy,  immunology*
Lymphocyte Subsets / drug effects*,  immunology
Middle Aged
Reg. No./Substance:
0/Antineoplastic Agents; 0/Interferon Type I, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An anti-LFA-1 monoclonal antibody (LDA-8) induces cellular aggregation of human lymphoblastoid cell ...
Next Document:  Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone m...